West Pharmaceutical Services (WST) Total Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $1.0 billion for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $1.0 billion, up 18.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 18.68% YoY), and the FY2025 annual result was $1.0 billion, up 13.34% from the prior year.
• Total Non-Current Liabilities came in at $1.0 billion for Q1 2026 at West Pharmaceutical Services, up from $1.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.0 billion in Q1 2026 to a low of $812.1 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $890.0 million (2023), against an average of $901.6 million.
• Across the five-year window, Total Non-Current Liabilities dropped 11.0% in 2022 and rose 18.68% in 2026, its largest moves.
• West Pharmaceutical Services' Total Non-Current Liabilities stood at $880.3 million in 2022, then rose by 1.1% to $890.0 million in 2023, then advanced by 1.0% to $898.9 million in 2024, then advanced by 13.34% to $1.0 billion in 2025, then climbed by 1.28% to $1.0 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $979.0 million (Q3 2025), per Business Quant data.